Photochemistry Research Laboratory, Department of Chemistry, Manonmaniam Sundaranar University, Abishekapatti, Tirunelveli, 627012, Tamil Nadu, India.
Appl Biochem Biotechnol. 2023 Dec;195(12):7397-7413. doi: 10.1007/s12010-023-04435-8. Epub 2023 Mar 31.
Two new heteroleptic Ru(II) polypyridyl complexes, [Ru(bpy)(B)]Cl (RBB) (bpy = 2,2'-bipyridine and B = 4,4'-bis(benzimidazolyl)-2,2'-bipyridine) and [Ru(phen)(B)]Cl (RPB), were synthesized, and the structural features were confirmed by the analytical and spectral tools such as FT-IR, H-NMR, and UV-Visible spectroscopy. We have explored the possibility of improving the selectivity of cytotoxic Ru(II) complex and their preliminary biological evaluation against MCF-7 and MG-63 cell lines and clinical pathogens. The results of the antimicrobial screening show that the ligand and complexes have a range of abilities against the species of bacteria and fungi that were tested. The anti-inflammatory activity of the compounds was found to be in the range of 30-75%. Molecular docking study was performed for these ligand and complexes to evaluate and analyze the anti-lymphoma cancer activity. Molecular docking score and the rank revealed the bonding affinity towards the site of interaction of the oncoprotein anaplastic lymphoma kinase (ALK).
两种新型的异双核钌（II）多吡啶配合物，[Ru（bpy）（B）]Cl（RBB）（bpy=2,2'-联吡啶，B=4,4'-双（苯并咪唑基）-2,2'-联吡啶）和[Ru（phen）（B）]Cl（RPB），被合成出来，并通过分析和光谱工具（如 FT-IR、H-NMR 和 UV-Visible 光谱）来确认其结构特征。我们探索了提高细胞毒性 Ru（II）配合物选择性的可能性，并对 MCF-7 和 MG-63 细胞系和临床病原体进行了初步的生物评价。抗菌筛选的结果表明，配体和配合物对所测试的细菌和真菌种类具有不同程度的抗菌能力。这些化合物的抗炎活性范围在 30-75%之间。对这些配体和配合物进行了分子对接研究，以评估和分析其抗淋巴瘤癌症的活性。分子对接得分和排名揭示了它们与间变性淋巴瘤激酶（ALK）的作用靶点的结合亲和力。
